In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report).

Craig-Hallum analyst Greg Palm maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report) today. The company’s shares opened ...

Fintel reports that on February 28, 2025, Craig-Hallum initiated coverage of MediWound (NasdaqGM:MDWD) with a Buy ...

Fintel reports that on February 12, 2025, Craig-Hallum initiated coverage of Myriad Genetics (NasdaqGS:MYGN) with a Buy recommendation. Analyst Price Forecast Suggests 57.19% Upside As of January 29, ...

As previously reported, Craig-Hallum downgraded Akamai (AKAM) to Hold from Buy with a $90 price target citing several ...

Arlo Technologies, Inc. (NYSE:ARLO – Get Free Report) shares saw an uptick in trading volume on Monday after Craig Hallum raised their price target on the stock from $15.00 to $17.00. Craig Hallum ...

As previously reported, Craig-Hallum analyst Albert Lowe initiated coverage of Eupraxia Pharmaceuticals (EPRX) with a Buy rating and $12 price target Eupraxia is leveraging its DiffuSphere drug ...

Globalstar (NYSEARCA:GSAT – Free Report) had its price target cut by Craig Hallum from $75.00 to $45.00 in a research report report published on Friday,Benzinga reports. They currently have a buy ...

As of February 19, 2025, the average one-year price target for MediWound is $29.58/share. The forecasts range from a low of $25.25 to a high of $37.80. The average price target represents an ...